CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.34
+2.63%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.31
From 52W high−65.33%
Volume2.05M
Market cap$509.88M
P/E (TTM)—
P/S (TTM)27.9x
Div yield—
Key dataOct 19, 2026
Open
$2.31
From 52W high
−65.33%
Volume
2.05M
Market cap
$509.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
P/E (TTM)
—
RSI (14)
34.7
MomentumView details →
1D Return
+2.63%
YTD Return
−45.89%
SummaryUpdated Jun 1, 2026
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is an oncology-focused biopharmaceutical company founded in 2008 and headquartered in South San Francisco, California. The company went public in October 2015 and has developed a proprietary technology platform called Probody therapeutics for creating conditionally activated cancer treatments. CytomX operates primarily as a research and development organization, advancing both internal drug candidates and partnered programs with major pharmaceutical companies including Bristol-Myers Squibb, Amgen, Astellas, and others.
Similar companies
Latest newsMore news →